159 related articles for article (PubMed ID: 35090351)
1. Bezlotoxumab for Prevention of Recurrent
Askar SF; Kenney RM; Tariq Z; Conner R; Williams J; Ramesh M; Alangaden GJ
J Pharm Pract; 2023 Jun; 36(3):584-587. PubMed ID: 35090351
[No Abstract] [Full Text] [Related]
2. Cost-effectiveness of Bezlotoxumab Compared With Placebo for the Prevention of Recurrent Clostridium difficile Infection.
Prabhu VS; Dubberke ER; Dorr MB; Elbasha E; Cossrow N; Jiang Y; Marcella S
Clin Infect Dis; 2018 Jan; 66(3):355-362. PubMed ID: 29106516
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness Analysis of Bezlotoxumab Added to Standard of Care Versus Standard of Care Alone for the Prevention of Recurrent Clostridium difficile Infection in High-Risk Patients in Spain.
Salavert M; Cobo J; Pascual Á; Aragón B; Maratia S; Jiang Y; Aceituno S; Grau S
Adv Ther; 2018 Nov; 35(11):1920-1934. PubMed ID: 30328061
[TBL] [Abstract][Full Text] [Related]
4. Bezlotoxumab in the treatment of Clostridioides difficile infections: a real-life experience.
Olmedo M; Kestler M; Valerio M; Padilla B; Rodríguez González C; Chamarro E; Machado M; Álvarez-Uría A; Alcalá L; Muñoz P; Bouza E
Rev Esp Quimioter; 2022 Jun; 35(3):279-283. PubMed ID: 35279984
[TBL] [Abstract][Full Text] [Related]
5. Bezlotoxumab: A Review in Preventing Clostridium difficile Infection Recurrence.
Deeks ED
Drugs; 2017 Oct; 77(15):1657-1663. PubMed ID: 28865041
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of bezlotoxumab to prevent recurrent Clostridioides difficile infection (CDI) in patients with multiple prior recurrent CDI.
Skinner AM; Tan X; Westman C; Birris T; Drwiega EN; Wang MS; Johnson S
Anaerobe; 2023 Dec; 84():102788. PubMed ID: 37931679
[TBL] [Abstract][Full Text] [Related]
7. Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infection: 12-Month Observational Data From the Randomized Phase III Trial, MODIFY II.
Goldstein EJC; Citron DM; Gerding DN; Wilcox MH; Gabryelski L; Pedley A; Zeng Z; Dorr MB
Clin Infect Dis; 2020 Aug; 71(4):1102-1105. PubMed ID: 31883370
[TBL] [Abstract][Full Text] [Related]
8. A budget impact analysis of bezlotoxumab versus standard of care antibiotics only in patients at high risk of CDI recurrence from a hospital management perspective in Germany.
Jakobs F; Wingen-Heimann SM; Jeck J; Kron A; Cornely OA; Kron F
BMC Health Serv Res; 2021 Sep; 21(1):939. PubMed ID: 34496836
[TBL] [Abstract][Full Text] [Related]
9. Real-World Comparison of Bezlotoxumab to Standard of Care Therapy for Prevention of Recurrent Clostridioides difficile Infection in Patients at High Risk for Recurrence.
Johnson TM; Molina KC; Howard AH; Schwarz K; Allen L; Huang M; Bajrovic V; Miller MA
Clin Infect Dis; 2022 May; 74(9):1572-1578. PubMed ID: 34665248
[TBL] [Abstract][Full Text] [Related]
10. Bezlotoxumab: A Novel Agent for the Prevention of Recurrent Clostridium difficile Infection.
Kufel WD; Devanathan AS; Marx AH; Weber DJ; Daniels LM
Pharmacotherapy; 2017 Oct; 37(10):1298-1308. PubMed ID: 28730660
[TBL] [Abstract][Full Text] [Related]
11. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection.
Wilcox MH; Gerding DN; Poxton IR; Kelly C; Nathan R; Birch T; Cornely OA; Rahav G; Bouza E; Lee C; Jenkin G; Jensen W; Kim YS; Yoshida J; Gabryelski L; Pedley A; Eves K; Tipping R; Guris D; Kartsonis N; Dorr MB;
N Engl J Med; 2017 Jan; 376(4):305-317. PubMed ID: 28121498
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of Bezlotoxumab for Prevention of Recurrent
Johnson TM; Howard AH; Miller MA; Allen LL; Huang M; Molina KC; Bajrovic V
Open Forum Infect Dis; 2021 Jul; 8(7):ofab294. PubMed ID: 34262988
[TBL] [Abstract][Full Text] [Related]
13. Genetic Association Reveals Protection against Recurrence of
Shen J; Mehrotra DV; Dorr MB; Zeng Z; Li J; Xu X; Nickle D; Holzinger ER; Chhibber A; Wilcox MH; Blanchard RL; Shaw PM
mSphere; 2020 May; 5(3):. PubMed ID: 32376702
[TBL] [Abstract][Full Text] [Related]
14. European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults.
van Prehn J; Reigadas E; Vogelzang EH; Bouza E; Hristea A; Guery B; Krutova M; Norén T; Allerberger F; Coia JE; Goorhuis A; van Rossen TM; Ooijevaar RE; Burns K; Scharvik Olesen BR; Tschudin-Sutter S; Wilcox MH; Vehreschild MJGT; Fitzpatrick F; Kuijper EJ;
Clin Microbiol Infect; 2021 Dec; 27 Suppl 2():S1-S21. PubMed ID: 34678515
[TBL] [Abstract][Full Text] [Related]
15. The effect of bezlotoxumab for prevention of recurrent Clostridium difficile infection (CDI) in Japanese patients.
Mikamo H; Aoyama N; Sawata M; Fujimoto G; Dorr MB; Yoshinari T
J Infect Chemother; 2018 Feb; 24(2):123-129. PubMed ID: 29097028
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Monoclonal Antibodies Against Clostridioides difficile Toxins for Prevention of Recurrent Clostridioides difficile Infection: A Systematic Review and Meta-Analysis.
Akiyama S; Yamada A; Komaki Y; Komaki F; Micic D; Sakuraba A
J Clin Gastroenterol; 2021 Jan; 55(1):43-51. PubMed ID: 32053529
[TBL] [Abstract][Full Text] [Related]
17. Analysis of C. difficile infection-related outcomes in European participants in the bezlotoxumab MODIFY I and II trials.
Bouza E; Cornely OA; Ramos-Martinez A; Plesniak R; Ellison MC; Hanson ME; Dorr MB
Eur J Clin Microbiol Infect Dis; 2020 Oct; 39(10):1933-1939. PubMed ID: 32504314
[TBL] [Abstract][Full Text] [Related]
18. Bezlotoxumab: Could This be the Answer for Clostridium difficile Recurrence?
Chapin RW; Lee T; McCoy C; Alonso CD; Mahoney MV
Ann Pharmacother; 2017 Sep; 51(9):804-810. PubMed ID: 28480750
[TBL] [Abstract][Full Text] [Related]
19. Bezlotoxumab during the first episode of Clostridioides difficile infection in patients at high risk of recurrence.
Escudero-Sanchez R; Ramos-Martínez A; Caballero-Bermejo AF; Díaz-Pollán B; Ruiz-Carrascoso G; Samperio MO; García PM; Amador PM; Romo FG; Segarra OM; Jiménez GN; Del Campo Albendea L; García AM; Cobo J
Eur J Clin Microbiol Infect Dis; 2024 Mar; 43(3):533-540. PubMed ID: 38236366
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of bezlotoxumab in preventing the recurrence of Clostridioides difficile infection: an Italian multicenter cohort study.
Meschiari M; Cozzi-Lepri A; Cervo A; Granata G; Rogati C; Franceschini E; Casolari S; Tatarelli P; Giacobbe DR; Bassetti M; Pinna SM; De Rosa FG; Barchiesi F; Canovari B; Lorusso C; Russo G; Cenderello G; Cascio A; Petrosillo N; Mussini C
Int J Infect Dis; 2023 Jun; 131():147-154. PubMed ID: 37030653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]